DOCUMENTS

Early rheumatic heart disease is a recognized intermediate on the pathway to advanced rheumatic heart disease
SAVAC TAWG (Technical Advisory Working Group) meeting reports from SAVAC Forum in Brisbane on June 1, 2025.
Models of Vaccine Finance and Their Potential Application to Group A Streptococcus Vaccines
No compelling evidence vaccination with Streptococcus pyogenes group A carbohydrate elicits cross-reactive rheumatic fever autoantibodies
Full Value of Vaccine Assessment
  • Group A Streptococcus: Full Value of Vaccine Assessment (FVVA) ReportDownload
Strep A Vaccine Industry Forum: Catalyzing Industry Investment In Strep A Vaccine R&D
  • SAVAC Industry Forum Report_2024.4.1.pdfDownload
SAVAC 2.0 immunoassay workshop in Abu Dhabi on 3Nov 2023
  • SAVAC 2.0 workshop for immunoassay_3Nov2023.pdfDownload
List of publications from SAVAC 1.0

SAVAC Protocols in OFID
  • All articlesLink
  • Harmonizing Surveillance Methodologies for Group A Streptococcal DiseasesLink
  • Standardization of Epidemiological Surveillance of Group A Streptococcal Pharyngitis Link
  • Standardization of Epidemiological Surveillance of Group A Streptococcal ImpetigoLink
  • Standardization of Epidemiological Surveillance of Group A Streptococcal CellulitisLink
  • Standardization of Epidemiological Surveillance of Invasive Group A Streptococcal Infections Link
  • Standardization of Epidemiological Surveillance of Acute Rheumatic FeverLink
  • Standardization of Epidemiological Surveillance of Rheumatic Heart DiseaseLink
  • Standardization of Epidemiological Surveillance of Acute Poststreptococcal GlomerulonephritisLink

Data Purpose Matrix
  • Moore SAVAC DPM CID2022.pdfDownload

SAVAC NPJ Vaccines health economics papers
  • Modeling the potential health impact of prospective Strep A vaccinesLink
  • The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation effortsLink
  • Optimal global spending for group A Streptococcus vaccine research and development Link
  • Global economic burden per episode for multiple diseases caused by group A StreptococcusLink
  • A Strep A vaccine global demand and return on investment forecast to inform industry research and development prioritizationLink

NPJ Vaccine pipeline
  • The Streptococcus pyogenes vaccine landscapeLink

Safety paper
  • Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing MonitoringLink

Immune correlates paper
  • Correlates of immunity to Group A Streptococcus: a pathway to vaccine developmentLink
WHO expert review of Group A Streptococcus vaccines: Hybrid Consultation by IVIR-AC and PDVAC, London, UK, 30 September 2022
  • who-expert-review-of-gas-vx-exec-summary-pdvac-and-ivirac-final.pdfDownload
SAVAC 2nd Stakeholders meeting Report 06JUNE2022
  • SAVAC 2nd Stakeholders meeting Report 06JUNE2022.pdfDownload
Presentation slides at the second SAVAC Stakeholders Meeting, 06 June 2022
  • 1. A strategic approach to understand strep A disease burden_Jonathan Carapetis.pdfDownload
  • 2. Immunologic protection and correlates_Shiranee Sriskandan.pdfDownload
  • 3. Strep A Vaccine Safety Considerations and Guidance during Development_Edwin Asturias.pdfDownload
  • 4. Potential impact of prospective strep A vaccines on the global burden of disease_model based analysis_Kaja Abbas.pdfDownload
  • 5. Global economic burden for Strep A infections and cost effectiveness analysis for a hypothetical Strep A vaccine_Jung Seok Lee.pdfDownload
  • 6. The full health economic social benefits of vaccination_conceptual framework and application to Strep A vaccines_Dan Cadarette.pdfDownload
  • 7. The Effect of a Prospective Vaccine Against Group A Streptococcus on Global Antibiotic Consumption for Sore Throat_Jeff Cannon.pdfDownload
  • 8. Global health and economic benefits _Maddalena Ferranna.pdfDownload
  • 9. Business Case for Industry Investment in Strep A Vaccine R&D_Don Walkinshaw.pdfDownload
  • 10. Optimal Global Spending for Group A Streptococcus Vaccine Research and Development_Dan Tortorice.pdfDownload
SAVAC Stakeholders meeting Report 13JUNE2021
  • SAVAC Stakeholders meeting Report 13JUNE2021.pdfDownload
SAVAC High Level Development Strategy 8MAY2020
  • SAVAC High Level Development Strategy 8MAY2020.pdfDownload
Vekemans WHO GAS vaccine R&D roadmap CID 2019
  • Vekemans WHO GAS vaccine R&D roadmap CID 2019.pdfDownload
WHO-IVB-18.07-WHO Preferred Product Characteristics for GAS Vaccines 2018
  • WHO-IVB-18.07-WHO Preferred Product Characteristics for GAS Vaccines 2018.pdfDownload
WHO-IVB-18.08-GAS Vaccine Develoment Technology Roadmap 2018
  • WHO-IVB-18.08-GAS Vaccine Develoment Technology Roadmap 2018.pdfDownload